Cabotegravir is indicated for usage in adults and adolescents weighing a minimum of 35kg who are at greater HIV-1 infection risk. Credit: elenavolf / Shutterstock.com.

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for two new formulations of ViiV Healthcare’s cabotegravir, offering a new prevention option for sexually transmitted HIV-1 infection.

The approved products include Apretude 30mg film-coated tablets and Apretude 600mg prolonged-release suspension for injection, both intended for use as pre-exposure prophylaxis (PrEP).

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Cabotegravir, now authorised as tablets and as a long-acting injection, is indicated for usage in adults and adolescents weighing a minimum of 35kg who are at greater HIV-1 infection risk.

The 600mg long-acting injection, administered every two months, is the first injectable treatment for HIV prevention approved in the UK. This regimen begins with two initial monthly injections, followed by one injection every two months.

Prior to starting cabotegravir, people must test negative for HIV.

See Also:

An oral lead-in with cabotegravir 30mg tablets daily for one month may be used to assess suitability for the injection.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The MHRA’s decision is based on evidence from two studies demonstrating significant reductions in HIV-1 incidence with cabotegravir versus standard PrEP comprising tenofovir disoproxil fumarate/emtricitabine.

One study, involving approximately 4,500 HIV-negative cisgender men and transgender women, showed a 66% decrease in HIV-1 incidence with cabotegravir.

Another study with over 3,200 HIV-negative cisgender women indicated an 88% reduction in the incidence.

Headache, diarrhoea, pyrexia, and changes in liver function were found to be the common side effects linked to cabotegravir usage.

MHRA Healthcare Quality and Access interim executive director Julian Beach said: “Keeping patients safe and enabling their access to high quality, safe and effective medical products are key priorities for us.

“We’re assured that the appropriate regulatory standards for the approval of this medicine have been met. As with all products, we will keep its safety under close review.”